Results for "Summit Therapeutics"

Biotechnology firm Summit Therapeutics reports promising clinical data suggesting its oncology treatment outperforms Merck's competing cancer therapy.

Shares of Nutanix, JM Smucker, and Summit Therapeutics all rose sharply during trading hours, reflecting positive investor sentiment and sector-specific catalysts. Market analysts point to varied drivers behind each company’s recent price movement.

Summit Therapeutics saw its stock rise after its partner Akeso secured a label expansion in China for its leading drug, indicating positive regulatory developments.

Summit Therapeutics released its second-quarter financial results, reporting a GAAP EPS of -$0.28, which managed to beat analyst estimates by $0.01.

Summit Therapeutics has withdrawn a planned $500 million stock offering just one day after its initial filing.

Summit Therapeutics has filed for a $500 million common stock offering, leading to a more than 9% slide in its shares.

H.C. Wainwright has lowered its price target for Summit Therapeutics Inc. (SMMT) stock.

Summit Therapeutics has been identified as the leader among large-cap healthcare stocks for year-over-year capital expenditure growth.

Summit Therapeutics Inc. is concentrating its efforts on the clinical trial of Ivonescimab, a drug being developed for the treatment of non-small cell lung cancer.

An earnings preview for Summit Therapeutics' fourth quarter of 2025 has been published.

Shares of clinical-stage biotech company Summit Therapeutics surged after the company reported promising patient survival results from its latest clinical trials.

Guggenheim Securities has reaffirmed its investment ratings for both Summit Therapeutics and Dick’s Sporting Goods, citing recent clinical trial developments and standard market evaluations.

Summit Therapeutics has outlined November 14 as the FDA PDUFA date for its ivonescimab Biologics License Application (BLA) and plans for HARMONi-3 PFS in the second half of 2026.

An investment analysis evaluates Recursion Pharmaceuticals against Summit Therapeutics to determine which healthcare stock presents a better buying opportunity in 2026.

Summit Therapeutics (SMMT) has successfully raised $500 million through a public offering, bolstering its financial resources for future operations.

Summit Therapeutics (SMMT) has disclosed data from its Phase II AK112-206 clinical trial, providing an update on the drug's development and efficacy.

Analysts have offered their insights and perspectives on the financial performance and outlook of healthcare companies Adagene (ADAG) and Summit Therapeutics (SMMT).

An analysis highlights Summit Therapeutics (SMMT) as one of the best large-cap stocks trading under $30, detailing factors contributing to its strong performance.

Summit Therapeutics announced plans to conduct an interim progression-free survival (PFS) analysis for its HARMONi-3 squamous cohort in the second quarter of 2026, as the company continues to expand its clinical pipeline.

Clinical trial results indicate that Summit Therapeutics’ investigational drug ivonescimab meets key secondary endpoints for overall survival in non-small cell lung cancer patients. The promising interim data positions the treatment as a potential new standard in first-line therapy.

Summit Therapeutics has stated that a significant cash crunch could jeopardize its ability to continue operations, raising concerns about the company's future.

The chief financial officer of Summit Therapeutics has been identified as the highest-paid CFO among public companies for the year 2025.

Summit Therapeutics has announced the withdrawal of its proposed securities offering, citing unfavorable market conditions as the reason for the decision.

Cantor Fitzgerald has reiterated its 'Overweight' rating for Intuitive Machines following a major Space Force contract win and maintained its 'Overweight' rating for Summit Therapeutics amidst mixed clinical developments. These reiterations reflect the firm's ongoing assessment of both companies' market positions.

Financial analysts have identified Revolution Medicines, Inc. (RVMD) and Summit Therapeutics (SMMT) as top stock picks. Both companies are highlighted as strong investment opportunities in a rising market.

Summit Therapeutics concluded 2025 with robust cash reserves and increased investment in its clinical development programs.

Summit Therapeutics announced its fourth-quarter financial results, with Non-GAAP EPS of -$0.14, missing estimates by $0.12.